<DOC>
	<DOC>NCT02091752</DOC>
	<brief_summary>The aim of the study is to assess the efficacy and safety of restarting ruxolitinib after treatment interruption due to loss of response and/or adverse events.</brief_summary>
	<brief_title>A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>Confirmed diagnosis of PMF, PPV MF or PETMF, irrespective of JAK2 mutational status according to the 2008 revised International Standard Criteria Peripheral blast count &lt; 10% Requires therapy for MF in the opinion of the investigator Received prior monotherapy treatment with ruxolitinib for at least 12 consecutive weeks and experienced treatment interruption because of lossof response or adverse event Patients adhering to the Screening phase assessments and undergoing a a ruxolitinibfree washout period of a minimum of 1 week and a maximum of 8 weeks ECOG performance status 0, 1, 2, or 3 Adequate bone marrow function Written informed consent Patients not initially responding (primary resistance) to ruxolitinib therapy Patients who underwent a splenectomy or spleen radiation Patients currently scheduled for bone marrow transplant Patients who have discontinued ruxolitinib &lt; 14 days prior to screening Patients who are not able to receive a starting dose of ruxolitinib of at least 15 mg total daily dose Leukemic transformation Inadequate renal function Presence of clinically meaningful active bacterial, fungal, parasitic or viral infection which requires therapy Previous history of Progressive Multifocal Leukoencephalopathy (PML) Clinically significant cardiac disease or significant concurrent medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Primary Myelofibrosis</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>INC424</keyword>
	<keyword>Ruxolitinib</keyword>
</DOC>